"Randomized, double-blind phase 2 clinical trial evaluating the tolerance of two different markers of medicinal marijuana in patients with glioblastoma multiforme (GBM).", Because that is the full name of the study in question, was published at the end of May 2021 in Frontiers in Oncology . Cannabis is extremely popular among people suffering from cancer, including glioblastoma, which is why researchers wanted to investigate patients' reactions to standardized medical marijuana. Careful examination of the effects of marijuana on patients has a key role in ensuring the safety of patients during therapy and in the fight against possible side effects occurring during its course.
A randomized clinical trial in adult patients diagnosed with high-grade glioma was started with basic brain, blood, and cognitive tests. A retrospective control group was used to compare the secondary results.
Participants (n = 88) were on average 53.3 years old. Paired t-test assessing the Functional Assessment of Cancer Therapy in Brain Cancer (FACT-Br) between groups from baseline to week 12 showed that a 1: 1 ratio promoted both physical (p = 0.025) and functional (p = 0.014) performance . In addition, it improved sleep quality (p = 0.009). Analysis of changes from baseline to week 12 also showed that 11% of 61 participants experienced a reduction in disease, 34% were stable. There were no serious adverse events. Side effects included dry mouth, fatigue at night, dizziness, and somnolence.
The conclusions of the study shed new light on the possibilities that cannabis offers sufferers. A single dose of medical marijuana containing THC was well tolerated by patients, improved sleep and well-being as well as quality of life. The dose was safe and well-tolerated, and had no serious side effects.
"A Phase 2 Randomized Clinical Trial Assessing the Tolerability of Two Different Ratios of Medicinal Cannabis in Patients With High Grade Gliomas" https://www.frontiersin.org/articles/10.3389/fonc.2021.649555/full
